Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotech advancing novel therapies for fibro-inflammatory diseases. This news hub provides investors and researchers with essential updates on nebokitug (CM-101), the company's lead monoclonal antibody targeting CCL24 in conditions like primary sclerosing cholangitis (PSC) and systemic sclerosis.
Access timely reports on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes verified updates from Phase 2/3 trials, FDA/EMA designations, and scientific conference presentations. Key focus areas span biomarker validation, trial enrollment status, and intellectual property developments.
This resource serves as your central source for tracking Chemomab's progress in addressing high-need rare diseases. Bookmark this page for direct access to primary documents including SEC filings, peer-reviewed data publications, and official press releases. Check regularly for updates on the upcoming Phase 3 PSC trial and expansion into new fibrotic disease indications.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has appointed Donald R. Marvin as the new Chief Financial Officer, Executive Vice President, and Chief Operating Officer. With over 35 years of experience in corporate finance and operations, Mr. Marvin aims to utilize his expertise to advance Chemomab's clinical programs. The company is focused on innovative therapeutics for fibrotic and inflammatory diseases, notably its drug CM-101, which is currently in Phase 2 clinical trials for various conditions. The leadership change is seen as a strategic move to enhance Chemomab's growth and operational efficiency.
Chemomab Therapeutics (Nasdaq: CMMB) announced a webinar featuring Dr. Dinesh Khanna, an expert in systemic sclerosis (SSc), on November 3, 2021. The discussion will cover the treatment landscape and clinical utility of CM-101, a monoclonal antibody targeting CCL24. CM-101 is currently being evaluated in Phase 2 trials for various fibrotic conditions, including SSc. As SSc lacks approved disease-modifying treatments, Chemomab aims to address this unmet medical need with its innovative therapies.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced a collaboration with Leeds University to study CCL24's role in vascular damage related to systemic sclerosis (SSc), a severe autoimmune condition. Led by Professor Francesco Del Galdo, this partnership aims to deepen the understanding of CCL24's contribution to SSc pathology. Chemomab plans to assess its CCL24-neutralizing monoclonal antibody, CM-101, in a Phase 2 trial in SSc patients starting early next year, building on existing mechanistic data.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has appointed Dale R. Pfost, PhD, as its new Chief Executive Officer. He will replace co-founder Adi Mor, who will continue as Chief Scientific Officer. Dr. Pfost brings over 30 years of experience in the biotech industry, having successfully led six companies and overseen several public offerings. His appointment reflects a strategic expansion of the senior management team as Chemomab progresses with two ongoing Phase 2 studies and prepares for a third trial. Shareholder approval for his role is expected in Q4 2021.
Chemomab Therapeutics, Ltd (Nasdaq: CMMB), a clinical-stage biotech firm, will attend several investor conferences in September 2021. Key events include the Citi 16th Annual BioPharma Virtual Conference from September 8-10, the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, and the Oppenheimer Fall Healthcare Summit on September 22. The company's lead product, CM-101, a monoclonal antibody targeting fibrosis, is currently in Phase 2 trials for primary sclerosing cholangitis and systemic sclerosis. Further information can be found on their website.
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotech firm, reported its financial and operational results for Q2 2021. As of June 30, 2021, the company had $67 million in cash, sufficient to fund operations into mid-2023. The company is advancing three Phase 2 trials for its lead product, CM-101, targeting fibrosis-related diseases. The ongoing SPRING and SPLASH trials are set to yield data in 2022. Despite rising R&D and administrative expenses totaling $2.8 million, Chemomab remains optimistic about its pipeline and collaborations, particularly with AGC Biologics.
Chemomab Therapeutics, Ltd. (NASDAQ: CMMB) has expanded its partnership with AGC Biologics for the manufacturing of CM-101, a Phase II investigational drug targeting fibrosis-related diseases like Primary Sclerosing Cholangitis and Systemic Sclerosis. The agreement aims to optimize and upscale the manufacturing process for upcoming pivotal studies, with clinical trial materials produced in Copenhagen. CM-101 has shown promise in clinical trials, and the collaboration is expected to enhance manufacturing capabilities ahead of Phase 3 trials.
Chemomab Therapeutics (Nasdaq: CMMB) has announced a poster presentation at the International Liver Congress 2021 from June 23-26, 2021. Dr. Arnon Aharon will present findings related to the role of CCL24 in bile duct fibrosis in primary sclerosing cholangitis (PSC). This presentation, titled The peri-ductular CCL24 rich niche promotes bile duct fibrosis related liver damage in primary sclerosing cholangitis, highlights CCL24's significance in fibrosis-related diseases. Full poster access will be available on Chemomab's website post-event.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) reported positive financial and operational results for Q1 2021, with a cash position of $58.2 million following a $45 million private placement. Key highlights include positive Phase Ib data for CM-101 in nonalcoholic fatty liver disease (NAFLD) and the initiation of Phase IIa trials for both primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH). The company plans to start an additional Phase II trial for Systemic Sclerosis (SSc) by year-end 2021. Net loss remained stable at $1.7 million for the quarter.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced its CEO, Dr. Adi Mor, will present a corporate update at the Oppenheimer Virtual Rare and Orphan Disease Summit on May 21, 2021.
The event aims to share insights on Chemomab's innovative therapeutics targeting fibrosis-related diseases, particularly its monoclonal antibody CM-101, which is in clinical development for orphan diseases like Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc).
The presentation will be available online for 30 days following the event.
